Member Info for LTbeliever

You are right, this is the problem with their 'deals", ie the client is allowed to commit to zero orders!

"although there is no guarantee of the total number or timing of ordering of units, nor revenues to be derived from, the Agreement."

https://www.lse.co.uk/rns/TRAC/significant-long-term-agreement-bk8jr4cij4heab1.html

"Metir’s important new product line could be ready for field-testing by the end of 2026, subject to successful development and financing.'' Well, now we have the finance for 2026 development, just need the optimers.

https://www.turnerpope.com/wp-content/uploads/2025/11/Metirplc_AptamerGroupplc_11-9-2025_FINAL_BG.pdf

@OLTB, FWIW, with Sales of 2.3mln in H1 and the Contguard deal in H2 (which IMO means around 3mln Sales in H2), I think the Co is near to erasing oper. losses; if I am correct, then the 2 Directors opting to get new shares in lieu of cash is a good indicator of the SP being near or at the bottom.

I get you OLTB, tough one I must say; I'd rather, though, they pay him more interest than giving him more shares, diluting us. Double-edged knife!

So as of today, total shares increased from 65.5 mln appx to 73.1 mln i.e. around 10% dilution.

That's about 10.000 extra annually, over annual expenses of 2.5mln; I see your point OLTB but who else would lend the Co, 250k on a long-term, unsecured basis? And at what rate? We pay 20-25%pa on credit card debt, for example.

Although I am biased, IMO the silver lining is the signaling to the Mkt that the Co will afford - in 2026 - to pay more as interest to its CTO and that it's slowly getting its debts in order (including the extra shares=dilution, in lieu of the Directors' fees).

We will see what happens when these extra shares hit the market tomorrow AM.

Correction - loss was 300k in H1 2025, expenses appx 650k. I expect that expenses should rise to maybe 800k in H2 (more staff, investments in production expansion/ optimisations).

We had 1mln in H1, @38% margin; loss of about 400k. We had 34 LXs sold @11k each appx, with 3 produced weekly around the end of H1, with Co aiming to increase both production and margins.

For H2 2025, I assume 4 LXs sold weekly, and a small increase in the Sales price and Margins i.e. 1.2mln Rev @ 30%GM (400k GProfit); for simplicity, I have ignored sales of FXs; WRT reagents & SRB kits, I assume GM rising to 75% and Sales of 400k (i.e. 300k GProfit). Note that 250k due by Qatar will be received in Q1 2026, so ignored for 2025 calculations; therefore, for H2 2025, I expect Sales of 1500-1600k, GP of 700k and B/E or a small loss (less than 100k).

GLA, DYOR and looking forward to the Co's Trading update.

3 from yesterday, total GBP55k. Nice start!

0.90 to BUY; let's hope for a rerun above 1p soon!

Almost 2 months since the FDA-delay RNS, and in 3-4 weeks the annual AFS 'd also be released (if same as last year); it's very likely we'll have the FDA news between now and month end. Even if no p/ship news are announced with the ODD ones, the Co should make some comment/reference to such a p/ship, if close to a deal. IMO

Last year, issued on 5th Febr; will be nice to have some other news before that though.

Seems Mgt is confident about the near future, although the Exercise price of the Options will be very easy to clear; still, a positive sign, but let's see some Sales soon.

So far today, delayed trades of GBP68.000; more speculators? :))

3 delayed trades this morning, total value appx GBP28k; speculators?

0.83 to BUY;

fully funded, GMargins on the way up, business expanding, still news to come on Cryptosporidium aptamer + Trading update (in Jan, hopefully), on PFAS later in the year, 250k to be received in Q1 by the Qataris, possible sales from the Saudi exhibition end of Jan;

Exciting H1 IMO, GLA!

Co has a story to "sell" as we can see from the 2 successful fund raises near, or at the SP (still, dilutory for existing PIs) in just a few months to invest in expansion; it has a plan to deliver, new innovative equipment soon, it's expanding both the Sales & Support Team with the aim to double its distributors' network, as well as the utilisation of equipment already in use; if it manages to also increase the GMargin from equipment sales and sales of reagents/SRBs, it will be getting to a GM of over 50% in H1 2026.

We know that by April, cashflow will have increased a lot, so the "going concern" basis might have a 'gap" for Q1 2026; still, if the Co needs 100-200k to see it through to May, that'd be a less than 5% dilution (assuming the SP doesn't rise post-suspension on material news, reducing any dilution to 1-2%).

If not "big week", more likely "big month". SP will show us the way things will be going.

Nice one, thanks - an extract follows, which IMO gives a balanced view of NFX for new and existing investors:

"Nuformix remains a speculative but increasingly visible player within the fibrosis space, supported by clear regulatory tailwinds and a differentiated approach to drug reformulation. The next phase will depend heavily on the company’s ability to move NXP002 into the clinic through partnership funding, a milestone that would validate its cocrystal strategy and broaden investor confidence. Market expectations are now more balanced following the post-spike retracement, creating a valuation that reflects both the promise and the risks inherent in early stage development. Continued progress in regulatory interactions and exploratory clinical planning will be key determinants of sentiment. For investors prepared to embrace volatility, Nuformix offers exposure to a niche but expanding therapeutic area with meaningful unmet need."